Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Ladenburg Thalmann Initiates Coverage On Tryp Therapeutics with Buy Rating

Ladenburg Thalmann analyst Michael Higgins initiates coverage on Tryp Therapeutics (OTC:TRYPF) with a Buy rating.

byBenzinga Newsdesk

August 26, 2021

1 minute read

Ladenburg Thalmann analyst Michael Higgins initiates coverage on Tryp Therapeutics (OTC:TRYPF) with a Buy rating.

UBS Maintains Buy on Bilibili, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 4:03 PM

UBS analyst Felix Liu maintains Bilibili (NASDAQ:BILI) with a Buy and lowers the price target from $40 to $30.

BILI

India Forced Twitter To Put Government Agent On Its Payroll, Whistleblower Alleges

By Navdeep Yadav

Today, 4:03 PM

A former Twitter Inc's (NYSE: TWTR) security chief, in a disclosure to U.S. regulators, alleged that Narendra Modi's government forced the social media giant to put a government agent on the payroll.

GOOG

Analyst Ratings

Analyst Ratings for Consolidated Edison

By Benzinga Insights

Today, 4:03 PM

Analysts have provided the following ratings for Consolidated Edison (NYSE:ED) within the last quarter:

10 Biggest Price Target Changes For Wednesday

By Lisa Levin

Today, 4:03 PM

UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading.

ADBE

Ladenburg Thalmann Initiates Coverage On Tryp Therapeutics with Buy Rating

Related Posts

UBS Maintains Buy on Bilibili, Lowers Price Target to $30

India Forced Twitter To Put Government Agent On Its Payroll, Whistleblower Alleges

Analyst Ratings for Consolidated Edison

10 Biggest Price Target Changes For Wednesday